Development and Validation of the Anaphylaxis Quality of Life Scale for Adults

Background

Anaphylaxis is a severe and potentially life-threatening allergic reaction that can have a detrimental impact on quality of life (QoL). There are no validated scales to measure the impact of anaphylaxis on QoL of adults.

Objective

The aim of this study was to develop and assess the reliability and validity of a QoL scale for adults with anaphylaxis (Anaphylaxis Quality of Life Scale for Adults [A-QoL-Adults]).

Methods

All participants were recruited from a specialist allergy clinic and had a confirmed diagnosis of anaphylaxis (as per the World Allergy Organization diagnostic criteria) to food, drugs, venom, or latex or had spontaneous anaphylaxis. Interviews were conducted with 13 adults; data were analyzed using thematic analysis to extract items for a QoL scale. A prototype QoL scale was then completed by 115 participants alongside validated scales to measure generic QoL (World Health Organization Quality of Life Scale [Brief Version] [WHOQoL BREF]), anxiety and depression (Hospital Anxiety and Depression Scale [HADS]), and stress (Perceived Stress Scale [PSS]).

Results

The A-QoL-Adults scale has 21 items demonstrating excellent internal reliability (Cronbach α = 0.96). Factor analysis produced 3 subscales: Emotional Impact; Social Impact; and Limitations on Life. Each has excellent internal reliability (0.92, 0.92, and 0.91, respectively). Poorer anaphylaxis-related QoL (total A-QoL-Adults score and subscale scores) correlated significantly with poorer general QoL and greater anxiety, depression, and stress (all P < .01 with medium-to-large effect sizes).

Conclusions

The A-QoL-Adults scale is a reliable measure of QoL in adults with anaphylaxis and shows good construct validity. It will offer health care professionals a means to further understand the impact of anaphylaxis on adult patients and could help direct and monitor allergy management and the need for further psychological intervention.

Knibb RC, Huissoon AP, Baretto R, Ekbote A, Onyango-Odera S, Screti C, Newman KL, Krishna MT. Development and Validation of the Anaphylaxis Quality of Life Scale for Adults. J Allergy Clin Immunol Pract. 2022 Mar 5:S2213-2198(22)00224-0. doi: 10.1016/j.jaip.2022.02.023. Epub ahead of print.

PDF

Predictive Response to Immunotherapy Score: A Useful Tool for Identifying Eligible Patients for Allergen Immunotherapy

Mormile I, Granata F, Detoraki A, Pacella D, Della Casa F, De Rosa F, Romano A, de Paulis A, Rossi FW. Biomedicines. 2022 Apr 22;10(5):971. doi: 10.3390/biomedicines10050971.

Abstract

Stratification of patients in three groups according to the Predictive

Response to Immunotherapy Score (PRIS) results and their ΔMSS-24.

A specific predictive tool of allergen immunotherapy (AIT) outcome has not been identified yet. This study aims to evaluate the efficacy of a disease score referred to as Predictive Response to Immunotherapy Score (PRIS) to predict the response to AIT and identify eligible patients. A total of 110 patients diagnosed with allergic rhinitis with or without concomitant asthma were enrolled in this study. Before beginning sublingual immunotherapy (SLIT), patients were evaluated by analyzing clinical and laboratory parameters. A specific rating was assigned to each parameter to be combined in a total score named PRIS.

Breathing Better Starts with Understanding How Asthma and Allergy Are Connected

World Allergy Week June 5-11, 2022, will focus on airway allergies.

Milwaukee, WI. May 19, 2022. World Allergy Organization (WAO) will host World Allergy Week from June 5 to 11, 2022, to raise awareness about how asthma and allergic airway diseases are connected and how important it is for both physicians and patients to understand and manage both. 

Allergic airway diseases of the respiratory system are the most common chronic diseases in humans. These diseases such as asthma, allergic rhinitis, chronic rhinosinusitis, chronic cough, eosinophilic bronchitis, allergic bronchopulmonary mycosis (ABPM), and others often occur together. 

A rare type 1 hypersensitivity to latex in dental treatment setting and management

Shiva Shankar Bugude

Adv Dermatol Allergol 2022; XXXIX (2): 421-423

DOI: https://doi.org/10.5114/ada.2020.99949

Latex gloves are considered to be the most effective barrier to blood-borne pathogens. Latex allergies in health professionals and patients are not quite uncommon. Reactions to latex gloves can vary from minor irritation to allergic reactions. In finished latex products, protein allergens account for up to 2 percent by weight. Latex allergies clinically can manifest as contact dermatitis or immediate type I hypersensitivity or delayed type IV hypersensitivity. This scientific article presents 2 cases of latex allergy type I hypersensitivity and uneventful management. 

Article file

- A rare type 1.pdf  [0.11 MB]

Oral Janus kinase inhibitors in the treatment of atopic dermatitis: A systematic review and meta-analysis

SYSTEMATIC REVIEW Open Access

Kevin P. Lee,John Plante,Jeffrey E. Korte,Dirk M. Elston

https://doi.org/10.1002/ski2.133

Abstract

Background

Janus kinase (JAK) inhibitors are being evaluated as promising upcoming treatments for atopic dermatitis (AD)

Objectives

To systematically assess the efficacy of oral JAK inhibitors in patients with AD and provide comparisons among JAK inhibitors.

Keratinocytes: An Enigmatic Factor in Atopic Dermatitis

by 

Pamelika Das

,

Pappula Mounika

,

Manoj Limbraj Yellurkar

,

Vani Sai Prasanna

,

Sulogna Sarkar

,

Ravichandiran Velayutham

 * and

Somasundaram Arumugam

 *

Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER)-Kolkata, Chunilal Bhawan, 168 Maniktala Main Road, Kolkata 700054, West Bengal, India

Academic Editor: Cord Brakebusch

Cells 2022, 11(10), 1683; https://doi.org/10.3390/cells11101683

Received: 14 March 2022 / Revised: 4 May 2022 / Accepted: 9 May 2022 / Published: 19 May 2022

Abstract

Atopic dermatitis (AD), characterized by rashes, itching, and pruritus, is a chronic inflammatory condition of the skin with a marked infiltration of inflammatory cells into the lesion. It usually commences in early childhood and coexists with other atopic diseases such as allergic rhinitis, bronchial asthma, allergic conjunctivitis, etc. With a prevalence rate of 1–20% in adults and children worldwide, AD is gradually becoming a major health concern. Immunological aspects have been frequently focused on in the pathogenesis of AD, including the role of the epidermal barrier and the consequent abnormal cytokine expressions.

Primary eosinophilic gastrointestinal disorders and allergy: Clinical and therapeutic implications

Clin Transl Allergy. 2022 May; 12(5): e12146.

doi: 10.1002/clt2.12146

Carlo Maria Rossi, 1 Marco Vincenzo Lenti, 1 Stefania Merli, 1 Amelia Licari, 2 Martina Votto, 2 Gian Luigi Marseglia, 2 and Antonio Di Sabatino 1

Abstract

Primary eosinophilic gastrointestinal disorders (EGID) are increasingly prevalent, immune‐mediated, chronic conditions which primarily affect pediatric and young adult patients, leading to substantial disease burden, and poor quality of life. EGID may either involve single portions of the gastrointestinal tract (i.e., esophagus, stomach, small bowel, and colon) or a combination. Their strong association with allergic disorders has been recently recognized, and although their shared pathophysiological basis remains partly elusive, this feature greatly impacts the diagnostic and treatment work‐up.

Allergological study in patients vaccinated against COVID-19 with suspected allergic reactions

• Research
• Open Access
• 
  

• Vicente Jover Cerdá, 
• Ramón Rodríguez Pacheco, 
• Joan Doménech Witek, 
• Sonia Alonso Hernández, 
• Rafael Durán García, 
• Marina Real Panisello & 
• Francisco Manuel Marco de la Calle 

Allergy, Asthma & Clinical Immunology volume 18, Article number: 43 (2022) 

• details

Abstract

Background

One of the main barriers to vaccination against SARS-CoV-2 is the fear of developing hypersensitivity reactions to any of its components. Although these reactions are very rare, it is necessary to establish an effective protocol to detect patients at risk of developing them. The aim of this study was to evaluate hypersensitivity reactions in vaccinated patients in order to allow or not to complete the vaccination protocol.